Full-Time

Vice President

Process Sciences

Posted on 2/18/2025

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$275k - $350kAnnually

+ Bonus + Equity Incentive Plan

Expert

Seattle, WA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis

You match the following Lyell Immunopharma's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • MSc in biology or related scientific field with a minimum of 20 years' experience or PhD in immunology, biology, oncology, or a related field with at least 20 years' experience
  • Working knowledge of GMP regulations and experience interacting with regulatory agencies
  • Demonstrated ability to build effective and efficient teams, drive change, and motivate teams across multiple functions
  • Strong executive presence with the ability to lead executive discussions, focus on detail, and think strategically
  • Ability to drive Lean principles to increase productivity
Responsibilities
  • Assure cell therapy processes and analytics are characterized and optimized, and that lot release and characterization assays are compliant with regulatory guidelines
  • Author and review sections of CMC regulatory submissions and represent the process sciences technical functions in regulatory interactions
  • Play a critical leadership role in developing the operating paradigm for Process Sciences; this role is responsible for developing and establishing how Lyell will develop and transfer all aspects of cell therapy development and technology to support commercialization
  • Serve as the technical and strategic expert in cell therapy development, including selection, activation, transduction, formulation, cryopreservation, and virus characterization method development for quantifying strength, purity, and potency attributes
  • Serve as the technical and strategic expert in cell therapy analytical development, including flow cytometry, cell biology, and molecular biology compendial and product-specific test methods
  • Lead the development and implementation of protocols and procedures related to cell and analytical process development operations
  • Establish robust cell and analytical standard processes that enable clinical product development and GMP operations
  • Collaborate and work with Research to support technology and product development
  • Work with key stakeholders to develop execution plans for reducing cycle times while increasing yields and productivity
  • Identify and mitigate risks in manufacturing operations that could negatively impact the quality of patient therapies
  • Demonstrate outstanding technical acumen, operational understanding, and GMP compliance in building and running process sciences
  • Champion implementation of new technologies and systems
  • Role model Lyell Values and Lean Leader principles to establish a continuous improvement culture
  • Collaborate with Research, Manufacturing, Quality, and Supply Chain leaders on all aspects of cell therapy technologies, analytical development, process development, and GMP production
Desired Qualifications
  • Strong executive leadership experience in research, process development, and operations
  • Experience in GMP manufacturing, technology transfer, and implementation of new technologies in a regulated environment is preferred
  • Proven experience with assessing new technologies in a fast-paced, learning organization, preferably in a cross-functional setting where the impact of new technologies is evaluated across research, development, and commercial organizations
  • Strong scientific background and expertise in cell culture and virus products – prior experience in viral or cell therapy preferred
  • Experience in developing and effectively managing department annual operating budgets

Lyell Immunopharma focuses on developing advanced cell therapies specifically for treating solid tumors, which are cancerous tissue masses. The company utilizes T cells, a type of immune cell, and employs technologies like Gen-R and Epi-R to modify these cells genetically and epigenetically. This modification helps T cells effectively target and destroy cancer cells while overcoming challenges such as T cell exhaustion and maintaining their ability to renew themselves. Unlike many competitors, Lyell is dedicated to creating curative treatments for solid tumors, with a diverse product pipeline that explores various treatment methods. Their goal is to push the boundaries of cancer treatment by providing effective therapies where traditional methods have not succeeded.

Company Size

201-500

Company Stage

IPO

Total Funding

$479.6M

Headquarters

San Francisco, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of ImmPACT Bio enhances Lyell's CAR T-cell therapy capabilities.
  • Strategic partnership with MaxCyte boosts cell engineering and therapeutic development.
  • New leadership appointments strengthen Lyell's strategic direction and management.

What critics are saying

  • Increased competition in T-cell therapies may impact Lyell's market share.
  • Delays in clinical data results could lead to investor uncertainty.
  • Integration challenges from ImmPACT Bio acquisition may divert focus from core operations.

What makes Lyell Immunopharma unique

  • Lyell focuses on T cell reprogramming to treat solid tumors effectively.
  • Their proprietary Gen-R and Epi-R platforms address T cell exhaustion and stemness.
  • Lyell's diverse product pipeline explores multiple treatment modalities for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

1%

2 year growth

6%
Business News Today
Oct 25th, 2024
Lyell Immunopharma to acquire ImmPACT-are CAR T-cell therapies the future of oncology?

Lyell Immunopharma is making waves with its strategic acquisition of ImmPACT Bio, a move aimed at bolstering its T-cell therapy capabilities.

GlobeNewswire
Oct 24th, 2024
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s...

Seeking Alpha
Sep 10th, 2023
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma: once huge IPO now waiting for clinical data.

BioHealth Innovation
Jul 6th, 2023
Biohealth Innovation

ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.

ForexTV
Jul 5th, 2023
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer.